ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE SALES AGREEMENTArcutis Biotherapeutics, Inc. • May 6th, 2021 • Pharmaceutical preparations • New York
Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • May 6th, 2021 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Scott L. Burrows (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed by both parties (the “Effective Date”). This Agreement supersedes the Severance & Change in Control Agreement previously entered into by and between the Executive and the Company which was effective as of the first date on which the registration statement on Form S-1 for the initial public offering of the Company’s Common Stock was declared effective by the United States Securities and Exchange Commission or, if later, the date that the prior agreement was signed.
EXCLUSIVE DISTRIBUTION AGREEMENTExclusive Distribution Agreement • May 6th, 2021 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • Tennessee
This Exclusive Distribution Agreement (the “Agreement”) is made as of this 8th day of February, 2021 (the “Effective Date”), between Arcutis Biotherapeutics, Inc. a corporation with an address of 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361 (“Client”), and Cardinal Health 105, Inc., an Ohio corporation, with a place of business at 501 Mason Road, Suite 200, La Vergne, Tennessee, 37086 (“Cardinal Health”) each individually a (“Party”) and collectively (the “Parties”).
